WO2008127456A3 - Compositions pour l'inversion et la détoxification des anesthétiques et d'autres composés et procédés d'utilisation de ces compositions - Google Patents

Compositions pour l'inversion et la détoxification des anesthétiques et d'autres composés et procédés d'utilisation de ces compositions Download PDF

Info

Publication number
WO2008127456A3
WO2008127456A3 PCT/US2007/086642 US2007086642W WO2008127456A3 WO 2008127456 A3 WO2008127456 A3 WO 2008127456A3 US 2007086642 W US2007086642 W US 2007086642W WO 2008127456 A3 WO2008127456 A3 WO 2008127456A3
Authority
WO
WIPO (PCT)
Prior art keywords
anesthetics
methods
attenuating
toxins
drugs
Prior art date
Application number
PCT/US2007/086642
Other languages
English (en)
Other versions
WO2008127456A2 (fr
Inventor
David M Anderson
Vincent M Conklin
Benjamin C Cameransi
Original Assignee
Lyotropic Therapeutics Inc
David M Anderson
Vincent M Conklin
Benjamin C Cameransi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyotropic Therapeutics Inc, David M Anderson, Vincent M Conklin, Benjamin C Cameransi filed Critical Lyotropic Therapeutics Inc
Priority to AU2007351338A priority Critical patent/AU2007351338B2/en
Priority to JP2009540476A priority patent/JP2010512341A/ja
Priority to CA2672024A priority patent/CA2672024C/fr
Priority to EP07873662A priority patent/EP2107904A4/fr
Publication of WO2008127456A2 publication Critical patent/WO2008127456A2/fr
Publication of WO2008127456A3 publication Critical patent/WO2008127456A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés d'atténuation des effets toxiques ou médicalement indésirables des médicaments et des toxines chez un être humain par l'administration chez l'humain d'un formulation injectable comprise d'une dispersion de particules comprenant un matériel liquide cristallin lyotrope cubique inversé ou hexagonal inversé. Les particules absorbent ou adsorbent ou autrement séquestrent et atténuent l'effet des médicaments et des toxines et peuvent être utilisées comme un agent de sauvetage ou d'inversion, ou à titre prophylactique. L'invention est applicable en particulier à l'inversion des effets contraires des anesthétiques locaux délivrés systémiquement par inadvertance et à l'atténuation des effets thérapeutiques des anesthétiques généraux au cours du traitement.
PCT/US2007/086642 2006-12-07 2007-12-06 Compositions pour l'inversion et la détoxification des anesthétiques et d'autres composés et procédés d'utilisation de ces compositions WO2008127456A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2007351338A AU2007351338B2 (en) 2006-12-07 2007-12-06 Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
JP2009540476A JP2010512341A (ja) 2006-12-07 2007-12-06 麻酔薬および他の化合物の逆転および解毒用組成物ならびにその使用方法
CA2672024A CA2672024C (fr) 2006-12-07 2007-12-06 Compositions pour l'inversion et la detoxification des anesthetiques et d'autres composes et procedes d'utilisation de ces compositions
EP07873662A EP2107904A4 (fr) 2006-12-07 2007-12-06 Compositions pour l'inversion et la détoxification des anesthétiques et d'autres composés et procédés d'utilisation de ces compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86895006P 2006-12-07 2006-12-07
US60/868,950 2006-12-07

Publications (2)

Publication Number Publication Date
WO2008127456A2 WO2008127456A2 (fr) 2008-10-23
WO2008127456A3 true WO2008127456A3 (fr) 2008-12-11

Family

ID=39864561

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086642 WO2008127456A2 (fr) 2006-12-07 2007-12-06 Compositions pour l'inversion et la détoxification des anesthétiques et d'autres composés et procédés d'utilisation de ces compositions

Country Status (5)

Country Link
EP (1) EP2107904A4 (fr)
JP (1) JP2010512341A (fr)
AU (1) AU2007351338B2 (fr)
CA (1) CA2672024C (fr)
WO (1) WO2008127456A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871820C (fr) * 2012-05-10 2020-11-03 Painreform Ltd. Preparations de depot d'un principe actif hydrophobe et procedes de preparation associes
JP6255975B2 (ja) * 2012-12-27 2018-01-10 Jnc株式会社 液晶組成物、酸化防止剤および液晶表示素子

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922317A (en) * 1996-01-04 1999-07-13 The United States Of America As Represented By The Secretary Of The Navy Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria
WO2001022960A1 (fr) * 1999-09-30 2001-04-05 Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Traitement de l'asphyxie par le monoxyde de carbone
US20030133877A1 (en) * 1997-07-21 2003-07-17 Levin Bruce H. Apparatus for directed intranasal administration of a composition
US20040143021A1 (en) * 2003-01-21 2004-07-22 Larijani Ghassem E. Compositions and methods for improving recovery after general anesthesia
WO2005034872A2 (fr) * 2003-10-08 2005-04-21 Lyotropic Therapeutics, Inc. Excipients pour administration medicamenteuse a base de materiaux a phase cristalline liquide inversee
US20050101621A1 (en) * 2003-11-12 2005-05-12 Richard Lipsky Method for rapid detoxification of addiction
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69816778T2 (de) * 1997-09-09 2004-04-15 Lyotropic Therapeutics, Inc. Beschichtete teilchen, methode zu ihrer herstellung und verwendung
JP2005530142A (ja) * 2002-06-13 2005-10-06 リオトロピック セラピュティックス アイエヌシー． 標的物質を保持したナノ多孔質粒子
US20030232340A1 (en) * 2002-06-13 2003-12-18 David Anderson Nanoporous particle with a retained target

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922317A (en) * 1996-01-04 1999-07-13 The United States Of America As Represented By The Secretary Of The Navy Accelerated gas removal from divers' tissues utilizing gas metabolizing bacteria
US20030133877A1 (en) * 1997-07-21 2003-07-17 Levin Bruce H. Apparatus for directed intranasal administration of a composition
WO2001022960A1 (fr) * 1999-09-30 2001-04-05 Charlotte-Mecklenburg Hospital Authority Doing Business As Carolinas Medical Center Traitement de l'asphyxie par le monoxyde de carbone
US20040143021A1 (en) * 2003-01-21 2004-07-22 Larijani Ghassem E. Compositions and methods for improving recovery after general anesthesia
US20050119340A1 (en) * 2003-06-13 2005-06-02 David Anderson Treatment methods with low-dose, longer-acting formulations of local anesthetics and other agents
WO2005034872A2 (fr) * 2003-10-08 2005-04-21 Lyotropic Therapeutics, Inc. Excipients pour administration medicamenteuse a base de materiaux a phase cristalline liquide inversee
US20050101621A1 (en) * 2003-11-12 2005-05-12 Richard Lipsky Method for rapid detoxification of addiction

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2107904A4 *

Also Published As

Publication number Publication date
JP2010512341A (ja) 2010-04-22
EP2107904A4 (fr) 2010-06-02
AU2007351338A1 (en) 2008-10-23
AU2007351338B2 (en) 2013-04-04
EP2107904A2 (fr) 2009-10-14
CA2672024C (fr) 2014-07-08
CA2672024A1 (fr) 2008-10-23
WO2008127456A2 (fr) 2008-10-23

Similar Documents

Publication Publication Date Title
WO2014144130A3 (fr) Composition pharmaceutique comprenant un activateur d'ampk et un agent sérotoninergique et procédés d'utilisation correspondants
WO2011053792A3 (fr) Méthodes et compositions pour une libération prolongée de médicaments
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
WO2013158680A3 (fr) Compositions et méthodes comprenant du célécoxib ou composés apparentés et du dextrométhorphane
EA200701195A1 (ru) Содержащие цефалоспорин композиции с наночастицами и с контролируемым высвобождением
WO2008054454A3 (fr) Dérivés hétérocycliques contenant de l'azote, compositions pharmaceutiques, et leurs procédés d'utilisations en tant qu'agents antiviraux
AR070834A1 (es) Dosificacion y formulacion de aclidinio para el tratamiento de trastornos respiratorios
WO2007100675A3 (fr) Procédé de traitement de la cellulite
WO2009043987A9 (fr) Compositions antibiotiques a base d'huiles essentielles - prophylaxie et traitement d'infections nosocomiales
WO2006017188A3 (fr) Traitement adjuvant d’antipsychotiques atypiques à base de memantine dans des cas de schizophrénie
HK1125039A1 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
WO2006098603A3 (fr) Composition renfermant de l'isoorientine pour suppression d'histamine
WO2007112272A3 (fr) Formulations de diclofénac et de cyclodextrine bêta à faible dosage
WO2010129962A3 (fr) Traitement en combinaison d'agents hydroxypyridonates de décorporation d'actinide/lanthanide
WO2008112773A3 (fr) Droxidopa et composition pharmaceutique de celle-ci pour le traitement de l'hypotension véhiculée par voie neurale
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2008012796A3 (fr) Compositions pharmaceutiques comprenant ccl2 et leur utilisation dans le traitement d'une inflammation
SE0950392L (sv) Sammansättning för behandling av hudåkommor
WO2015035410A8 (fr) Traitement du cancer
WO2008070010A3 (fr) Rétablissement après une attaque
CO6220945A2 (es) Uso de una composicion que comprende formoterol y dipropianato de beclometasona para la prevencion y/o tratamiento de una exacerbacion de asma
WO2008127456A3 (fr) Compositions pour l'inversion et la détoxification des anesthétiques et d'autres composés et procédés d'utilisation de ces compositions
IL197783A (en) Polycyclic compounds, preparations containing them and polycyclic compounds for use in the treatment of synthetic respiratory virus infections
JP2011500589A5 (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07873662

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007351338

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2009540476

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2672024

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007351338

Country of ref document: AU

Date of ref document: 20071206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007873662

Country of ref document: EP